Therefore, we examined the antiproliferative activity of lenvatinib against nine HCC cell lines, and we showed that lenvatinib has inhibitory activity against HCC cell lines with activated FGF signaling pathways 20, 26; this proliferation inhibition was accompanied by suppressed FRS2 phosphorylation (Figs 1 and 2). The gene discussed is FRS2; the disease is hepatocellular carcinoma.